news

From 50,000 to 700,000 SKUs: Speed Parts Drives 20%+ Annual Growth with Maropost

SUNSHINE COAST, Australia, Sept. 2, 2025 /PRNewswire/ -- Speed Parts, one of Australia's top automotive parts retailers, has turbocharged its…

7 months ago

HarperCollins India to publish Chetan Bhagat’s new romance

NEW DELHI, Sept. 2, 2025 /PRNewswire/ -- HarperCollins India is delighted to present a new novel by Chetan Bhagat, an irresistible…

7 months ago

SERES Posts Robust H1 2025 Results: Revenue Hits CNY 62.4 Billion, Net Profit Up 81% to CNY 2.94 Billion, R&D Investment Soars nearly 155%

CHONGQING, China, Sept. 3, 2025 /PRNewswire/ -- On August 29, SERES announced its 2025 mid-year results, reporting strong growth across all…

7 months ago

Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit

Motion underscores that Abacus's claims lack merit as Lapetus, its key life expectancy provider, shut its doors August 31 FORT…

7 months ago

Coming Soon | GAC Will Officially Showcase Global Strategic Models at IAA Mobility 2025 in Munich

MUNICH, Sept. 3, 2025 /PRNewswire/ -- As one of the world's top five automotive exhibitions, IAA Mobility 2025 will officially…

7 months ago

TACC and CGT Unite to Drive Graphene Revolution

NEW DELHI, Sept. 2, 2025 /PRNewswire/ -- TACC Limited, a wholly owned subsidiary of HEG Limited and part of the…

7 months ago

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 - 15 in Copenhagen,…

7 months ago

Herbalife India Honored with ‘Sustainable Supply Chain Award’ at BIGBOX India 2025

BENGALURU, India, Sept. 2, 2025 /PRNewswire/ -- Herbalife India, a premier health and wellness company, community, and platform, proudly announces…

7 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

September 02, 2025 21:33 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…

7 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

7 months ago